Insulet (Nasdaq:PODD) today unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes. Acton, Massachusetts-based Insulet presented results from studies as well as user experience data for both type 1 and type 2 diabetes at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona, […]
Sweetch adds American Diabetes Association exec to its advisory board
Chronic condition therapeutic developer Sweetch announced today that Dr. Robert A. Gabbay has joined the company as an advisor. Gabbay currently serves as the chief scientific and medical officer at the American Diabetes Association, leading the organization’s efforts to drive discovery in diabetes research, care and prevention. He also serves as an associate professor of […]
Impel NeuroPharma rebrands to Impel Pharmaceuticals as part of corporate transformation
Impel NeuroPharma (Nasdaq:IMPL) announced today that it changed its name to Impel Pharmaceuticals as part of a corporate rebrand. Seattle-based Impel develops proprietary Precision Olfactory Delivery (POD) technology to treat patients suffering from diseases across a range of areas in addition to the central nervous system. The company’s Trudhesa nasal spray for treating migraine in […]
EMA gives positive opinion on Novo Nordisk’s human insulin with flexible storage
Novo Nordisk (NYSE:NVO) announced that the European Medicines Agency (EMA) granted a positive opinion on a storage update for insulin. EMA’s positive opinion relates to a proposed update to the storage conditions of two human insulins: Actrapid (short-acting insulin) and Insulatard (intermediate-acting insulin). Bagsværd, Denmark-based Novo Nordisk said in a news release that the EMA’s […]
Comera inks deal with Intas to reformulate infusion treatments into one-shot self-injections
Comera Life Sciences announced that it will collaborate with Intas Pharmaceuticals to develop a new generation of biologic medicines. Woburn, Massachusetts-based Comera will develop a differentiated formulation of an Intas product using its SQore formulation platform, while Ahmedabad, India-based Intas will provide research funding with the option to acquire global rights to the formulation through […]
How Insulet created its next-gen Omnipod 5
Insulet (NSDQ:PODD) added to its portfolio of life-changing diabetes management technologies when its Omnipod 5 received FDA clearance in January. Omnipod 5 provides easier glucose management, with no multiple daily injections, no tubes and zero fingersticks. Paired with Dexcom’s G6 continuous glucose monitoring (CGM) system, Omnipod 5 is the first tubeless, wearable, automated insulin delivery […]
Koru Medical names former Fresenius Kabi VP as chief technology officer
Koru Medical Systems (Nasdaq:KRMD) announced that it appointed medtech veteran Brian Case as its new chief technology officer (CTO). With more than 20 years of experience in medtech R&D, Case joins after spending more than 16 years at Fresenius Kabi as VP of R&D. Before Fresenius Kabi, he served as an R&D program manager for […]
Carbon Health launches new virtual diabetes management program
Carbon Health announced today that it launched its diabetes program through its full integration with Steady Health. San Francisco-based Carbon Health acquired Steady Health and its platform for using continuous glucose monitoring (CGM) to personalize diabetes care in June 2021. The platform aims to simplify diabetes management with CGM monitoring and logging that provides a […]
FDA grants STeP designation for Pear Therapeutics’ neurobehavioral digital therapeutic
Pear Therapeutics (Nasdaq:PEAR) announced today that it received STeP designation from the FDA for its Pear-010 product candidate. Boston-based Pear Therapeutics designed its Pear-010 prescription digital therapeutic (PDT) candidate to provide a neurobehavioral intervention (virtual reality-delivered pain reduction) to patients 18 and older with acute postoperative and acute postprocedural pain. Get the full story at our […]
Lyra Therapeutics closes $100.5M private placement
Lyra Therapeutics (Nasdaq:LYRA) announced today that it closed its previously announced private placement worth $100.5 million. The company announced last week that, in the private placement, investors had the option in the private placement to purchase either shares of Lyra’s common stock at $4.22 per share or, in lieu thereof, pre-funded warrants to purchase shares […]
